Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01037543 · ClinicalTrials.gov registry record · Phase 1

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

A Phase 1 study of Healthy, sponsored by Hanmi Pharmaceutical Company Limited.

Completed
Registry status
Phase 1
Development phase
84
Enrollment target
1
Study location

NCT01037543: Completed Phase 1 study of Healthy, sponsored by Hanmi Pharmaceutical Company Limited.

NCT01037543 is a Phase 1 study of Healthy that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 84 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01037543, a Phase 1 study of Healthy, has completed, sponsored by Hanmi Pharmaceutical Company Limited.

COMPLETED
Registry status
Phase 1
Development phase
84 participants
Enrollment target
1
Study location

Study Summary

Study Design * Randomized, double-blind, placebo-controlled, escalating single-dose design. * Six ascending dose cohorts * In each cohorts, subjects will be randomized to receive a single dose of HM10460A, placebo (negative control), or Neulasta® (positive control). * Primary Objective * to assess the safety and tolerability of single escalating subcutaneous doses of HM10460A in healthy adult Japanese and Caucasian subjects.

Conditions Studied

Interventions

  • DRUG HM10460A or placebo or Neulasta

Study Locations (1)

California

  • - California City

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2009-11
Est. Completion 2011-04
Phase Phase 1

What the Registry Record Tells You About NCT01037543

The ClinicalTrials.gov registry entry for NCT01037543 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (87% lower). The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which HM10460A or placebo or Neulasta is the first listed.

NCT01037543 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01037543 about?

NCT01037543 is a clinical study titled "Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects". Study Design * Randomized, double-blind, placebo-controlled, escalating single-dose design. * Six ascending dose cohorts * In each cohorts, subjects will be randomized to receive a single dose of HM10460A, placebo (negative control), or Neulasta® (positive control). * Primary Objective * to assess ...

What is the current status of trial NCT01037543?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2009-11. Estimated completion is 2011-04.

What conditions does trial NCT01037543 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01037543?

The interventions under investigation include: HM10460A or placebo or Neulasta (DRUG).

Who is sponsoring clinical trial NCT01037543?

This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01037543 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.